A comprehensive view of Gilead Sciences Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

WHO welcomes clinical trials showing zero HIV infections with Gilead's lenacapvir; WHO recommends global access pending further trials, calls for affordable pricing
Published: July 15, 2024 by CE Noticias Financieras
Gilead's HIV prevention trial of twice-yearly injectable lenacapavir shows 100% efficacy with zero infections, demonstrates superiority over Truvada; DMC to recommend offering open-label therapy
Published: June 20, 2024 by Business Wire
California Supreme Court to review decision allowing plaintiffs to sue pharmaceutical manufacturers for delaying development of new drugs; Gilead Life Sciences case may set precedent
Published: May 16, 2024 by Mondaq Business Briefing
Forty-eight pharma M&A deals worth €33.55B took place in Q1 2024; Novo Holdings led the top five acquisitions, with a €10.659B deal for Catalent followed by Gilead's €3.95B deal for CymaBay Therapeutics: Evaluate Pharma
Published: May 16, 2024 by CE Noticias Financieras (Latin America)
Gilead completes acquisition of CymaBay Therapeutics for US$4.3B, enhancing its liver disease treatment portfolio with lead product candidate seladelpar for primary biliary cholangitis; CymaBay now a wholly owned subsidiary of Gilead
Published: March 22, 2024 by Business Wire

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count